Older Americans screened for cancer despite limited benefits
the ONA take:
According to a new report in The Journal of the American Medical Association Internal Medicine, up to 50% of older people in the United States received cancer screening despite a high probability that they would die without cancer within the next 9 years. Trevor Royce, MD, MS, of the University of North Carolina at Chapel Hill and his colleagues agree that routine cancer screenings has minimal benefits for patients with a limited life expectancy.
In the study, the researchers assessed responses from 27,404 people at least 65 years old. Based on their responses, the researchers estimated their probability of death within the next 9 years and then identified which of those had recently been screened for breast, cervical, colon, and prostate cancers.
They found that 55% of men who had a 75% risk of death had received a prostate specific antigen (PSA) screening. Approximately 33% of women with a 75% risk of death received breast and cervical cancer screenings. In addition, 41% of people who were not likely to live another 10 years received colon cancer screenings.
The American Cancer Society and other professional societies recommend stopping PSA screening in men who are not expected to live another 10 years.
Despite potential risks, many are still screened for cancers toward the end of their lives.
Up to half of older people in the U.S. received cancer screenings even though there was a high likelihood that they would die within nine years without cancer, researchers report in JAMA Internal Medicine.
“There is general agreement that routine cancer screening has little likelihood to result in a net benefit for individuals with limited life expectancy,” write Dr. Trevor Royce and his fellow researchers from the University of North Carolina, Chapel Hill. Several professional societies have updated their cancer screening guidelines to suggest that people who aren't expected to live another 10 years should not be screened for certain cancers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|